There is no measured MOTS-c before and after. Zero randomized trials of the injected peptide have been published. What exists is observational: levels measured in people who were never given anything.
The short answer. Zero randomized trials of injected MOTS-c have been published. There is no measured before and after.
- Human data is observational: cohorts of 404 and 85 people whose own circulating levels were measured.
- The strongest human number is a correlation of R = −0.71, which is not the result of anyone taking anything.
- Roughly 40 preclinical studies support the mechanism. Treated mice gain insulin sensitivity and stamina.
MOTS-c is a 16-amino-acid peptide. Mitochondria encode it, so it is genuinely endogenous, and it does circulate in human blood. The mechanism work is strong. The clinical work does not exist. Zero randomized trials of injected MOTS-c have been published. The human findings come from cohorts of 404 and 85 people. Their own levels were measured, not changed. That is a correlation, not a result.
What the human studies actually did
This is the distinction the whole page turns on. An observational study measures what is already there. An interventional study gives someone something and measures what changes. Only the second produces a before and after.
Every human MOTS-c finding is the first kind. A cohort of 404 participants had circulating levels measured against health outcomes. A separate group of 85 healthy subjects produced a correlation of R = −0.71 between MOTS-c and a metabolic measure.
A correlation of −0.71 is strong. It is also not a result of taking anything. Nobody in those studies was injected with MOTS-c, so nothing in them can tell you what happens when you are.
The MOTS-c complete guide covers the full evidence base and where each number comes from.
The mechanism is the strongest part, and it is mice
MOTS-c has an unusually good mechanism story for a compound with no trials. The USC Cohen lab has mapped it across AMPK activation, CK2 binding, myostatin suppression and Bcl-2 interaction, and there are roughly 40 preclinical studies behind it.
The exercise link is the finding that drives most of the marketing: MOTS-c rises with exercise, which is a genuinely interesting piece of biology and is also the reason the causal arrow is so easy to get backwards.
MOTS-c has been used less frequently in disease treatment, and no effective method of applying MOTS-c in the clinic has been developed.
Zheng et al., Frontiers in Endocrinology, 2023Treated mice do gain insulin sensitivity and stamina. That is real and replicated. It is not a human outcome. MOTS-c benefits separates the two.
Why the exercise finding cuts both ways
MOTS-c goes up when people exercise. Two readings of that are available and they lead to opposite conclusions.
- MOTS-c drives the benefit. If so, giving it might reproduce some of the effect. This is the marketing reading.
- MOTS-c is a marker of the benefit. If so, raising it directly does nothing, the same way raising a thermometer does not warm a room.
Nobody has run the experiment that separates them, and until somebody does, every personal before-and-after has the same confound in it: people who start MOTS-c usually start training harder at the same time.
The same reasoning applies across this class — see SS-31 vs MOTS-c for how two mitochondrial peptides with different evidence bases compare.
What would count as a MOTS-c result
It is worth being concrete about the missing thing, because it is not exotic.
A randomized trial. Two groups. One gets injected MOTS-c, one gets placebo. Measure insulin sensitivity, or VO2 max, or grip strength, at a fixed timepoint. Publish it. That is the standard, and it has been met by peptides with far less mechanistic support than this one.
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
Reynolds et al., Nature Communications, 2021That title is a strong claim and it is supported — in mice, and in human association data. The gap between it and a clinical result is the gap this page is about. For a contrast, tesamorelin has a CT scan from 412 randomized adults.
How to read a MOTS-c before-and-after
Three checks:
- Was anyone given anything? If the study measured existing levels, it is not a before-and-after however large the cohort was.
- What changed alongside it? Training and diet almost always move at the same time, and this compound’s own biology says exercise raises it.
- Is the number from a mouse? Most of the striking ones are. MOTS-c dosage covers what the animal work administered.
None of that makes MOTS-c uninteresting. It makes it early. Those are different things, and the market has a strong incentive to blur them.
What to know now
- Zero randomized trials of injected MOTS-c have been published. There is no measured before and after.
- Human data is observational: cohorts of 404 and 85 people whose own circulating levels were measured.
- The strongest human number is a correlation of R = −0.71, which is not the result of anyone taking anything.
- Roughly 40 preclinical studies support the mechanism. Treated mice gain insulin sensitivity and stamina.
- MOTS-c rises with exercise, so it may be a marker of the benefit rather than its cause. Nobody has separated the two.
What we're watching
The missing study is ordinary: randomize, inject one arm, placebo the other, measure insulin sensitivity or VO2 max at a fixed timepoint. Given how well mapped the mechanism is, its absence after a decade is itself informative about how hard the peptide is to deliver. We are watching for any registered interventional trial of injected MOTS-c in humans, and for work that separates the marker reading of the exercise finding from the causal one.
Frequently asked questions
Are there real MOTS-c before and after results?
Not from trials. Zero randomized trials of injected MOTS-c have been published, so no measured change exists. The human data is observational, from cohorts where people's own circulating levels were measured rather than altered.
What does the R = -0.71 correlation mean?
That in a group of 85 healthy subjects, higher circulating MOTS-c tracked with a better metabolic measure. It is a strong association. It does not tell you what happens if you inject the peptide, because nobody in that study did.
How long does MOTS-c take to work?
There is no measured onset in humans, because there is no interventional human study. Timelines in circulation are extrapolated from animal work.
Does exercise raise MOTS-c?
Yes, that is a replicated finding. It cuts both ways: MOTS-c may be driving part of the exercise benefit, or it may simply be a marker of it. No study has separated those two readings.
Is MOTS-c worth taking?
That is a decision this page cannot make for you, but the honest state of the evidence is: strong mechanism, roughly 40 preclinical studies, good animal results, and no human interventional data at all.
What people actually report
These are self-reports, not evidence. No control group, no blinding, and no independent check that the vial held what the label claimed. They are collected here because people asking about MOTS-c deserve an answer rather than a refusal, and because what the community believes is itself worth knowing. Quotes are excerpts; each links to the original post.
Self-reports converge on energy. The most common claim is that fatigue lifts, and several posters report insomnia when they inject late in the day. People who report an effect usually describe it in days, not weeks. Fat-loss claims are rare. Almost nobody runs it alone: most stack it with SS-31, a GLP-1, or both, so nothing here is attributable to MOTS-c. Non-response is the other loud theme, and every thread has people who say they felt nothing at all. A smaller group reports injection-site reactions and itchy red lumps, and one widely read post reports anaphylaxis after a first dose. All of it is uncontrolled, unverified self-report.
Where the community and the published record disagree. The community and the evidence disagree on nearly everything measurable. The doses described in these threads run from about 0.5 mg to 3 mg, and posters report an effect within days. The only completed human trial gave 25 mg once daily for four weeks, and it did not test MOTS-c at all: it tested CB4211, which CohBar describes as "a novel and improved analog of MOTS-c," in 20 obese subjects with fatty liver disease. Its primary endpoints were safety and tolerability. It reported a 21% ALT reduction, a 6% glucose reduction, and only "a trend towards lower body weight." Energy was never measured. A commenter in r/Biohackers names the gap out loud: "The only trials other than mice started with a dose of 25 mg per day. People dropped their protocol to 2 to 4mg because 25mg per day is too expensive." The doses circulating online were set by price, not by a finding. The safety picture inverts too. The only adverse events above 10% in that trial were "transient and generally mild to moderate injection site reactions," while the highest-voted post about MOTS-c in r/Biohackers or r/Peptides is a user in the emergency room with anaphylaxis five minutes after a 1 mg first dose. One thing has changed since that trial. A Phase 2a study of MOTS-c itself (NCT07505745, sponsor Hudson Biotech, 120 adults with prediabetes and overweight or obesity, 12 weeks of once-daily dosing) began recruiting on February 2, 2026, with primary completion listed for February 14, 2027. It is the first human trial of the peptide itself rather than an analog, and it has not reported.
“Currently at the hospital after my first shot of Mots C (1 MG) as I started experiencing anaphylaxis after 5 minutes.”
“Ran a full course of SS31 followed by MOTS-C. Did nothing for me at all.”
“RETA/MOTS/DSIP/SS31 has made me feel 10 years younger on days that I normally would be counting the hours until I can try and sleep again.”
“I administered at 8AM and I didnt fall asleep until 3 AM lol.”
“within five days I was waking up multiple times a night, felt foggy and lightheaded all day, and had zero mental clarity”
“I also cover the reactions I see most often with patients, including histamine flares, fatigue, and why some people feel worse before they understand what their mitochondria can handle.”
Doctor Explains The Truth About MOTS-c & If It's Safe (nobody is saying this)
Posts are quoted under fair use and linked to their authors. Nothing on this page is hosted here, and no claim above has been verified beyond confirming that the person wrote it.
References
- Lee, C., Zeng, J., Drew, B. G., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443–454. https://doi.org/10.1016/j.cmet.2015.02.009
- Reynolds, J. C., Lai, R. W., Woodhead, J. S. T., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12, 470. https://doi.org/10.1038/s41467-020-20790-0
- Zheng, Y., Wei, Z., & Wang, T. (2023). MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology, 14, 1120533. https://doi.org/10.3389/fendo.2023.1120533
- Kumagai, H., Coelho, A. R., Wan, J., et al. (2021). MOTS-c reduces myostatin and muscle atrophy signaling. American Journal of Physiology — Endocrinology and Metabolism, 320(4), E680–E690. https://doi.org/10.1152/ajpendo.00275.2020
- Kumagai, H., Kim, S. J., Miller, B., et al. (2024). MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience, 27(11), 111212. https://doi.org/10.1016/j.isci.2024.111212
- Yin, Y., Pan, Y., He, J., et al. (2021). The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacological Research, 175, 105987. https://doi.org/10.1016/j.phrs.2021.105987
- Lu, H., Fan, L., Zhang, W., et al. (2024). The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. Cell Reports, 43(1), 113587. https://doi.org/10.1016/j.celrep.2023.113587
- Yi, X., Hu, G., Yang, Y., Li, J., Jin, J., & Chang, B. (2023). Role of MOTS-c in the regulation of bone metabolism. Frontiers in Physiology, 14, 1149120. https://doi.org/10.3389/fphys.2023.1149120